SCHEMBL12480284

SCHEMBL12480284

O=C(Nc1cccc(OC(F)(F)F)c1F)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ PDK1 Q15118 1/20 0.44
▸ PDK2 Q15119 1/20 0.44
▸ PDK3 Q15120 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KLK7 P49862 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ EPHX2 P34913 2/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PARP14 Q460N5 1/20 0.40
▸ KCNK3 O14649 1/20 0.40
▸ KCNK9 Q9NPC2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8084614 0.89 GAA (0.57) ANO1GAAPDK1PDK2PDK3
SCHEMBL29177412 0.86 GAA (0.44) GAAPDK1PDK2PDK3PDK4
SCHEMBL29739342 0.79 NPC1 (0.52) GAAMAPTL3MBTL1EPHX2RXFP1
SCHEMBL3596918 0.78 TP53 (0.50) ANO1PDK1PDK2PDK3PDK4
SCHEMBL17609898 0.78 L3MBTL1 (0.41) GAAMAPTL3MBTL1CYP2C9CYP1A2
SCHEMBL2088365 0.78 EPHX2 (0.48) ANO1GAAL3MBTL1EPHX2CYP2C9
SCHEMBL2226280 0.76 PDK1 (0.72) GAAPDK1PDK2PDK3PDK4
SCHEMBL18554430 0.76 EPHX2 (0.43) EPHX2CYP2C9CFD
SCHEMBL28859839 0.76 NAMPT (0.43) ANO1GAAHTTRXFP1KCNK3
SCHEMBL18554429 0.76 EPHX2 (0.43) EPHX2CYP2C9CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 — — US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 — — EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 — — US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 ANO1 3950/4885GAA 3091/4885PDK1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback